PerpEquities

Equity · Healthcare

AbbVie Inc. (ABBV) perpetual futures

AbbVie Inc. is a global biopharmaceutical company developing and commercializing advanced medicines for immunology, oncology, virology, gastroenterology, neurology, and other therapeutic areas.

$260.22-0.6%NYSE closed
Open in terminal

Price chart

Not enough price history yet for this newly listed market.

Use the left and right arrow keys to inspect points on the chart.

Collecting venue price data...
venue perp mark · Gate.io (ABBV/USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

1/2 live markets
Venues
2
Live markets
1/2
24h volume
$3K
Open interest
$27.5K
Best liquidity
$1.9K
Gate.io
Tightest spread
+188.4 bps
Gate.io
Highest volume
$3K
Gate.io
Settlement mix
USDT · 2/2
Perp/spot vol.
0.00x
Spot volume $716M
OI / float
0.00%
Float $458.9B
Spot performance
1D-0.54%
5D+0.63%
1M+6.77%
6M+10.21%
YTD+13.92%
1Y+22.21%

Venue matrix

2 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
Gate.ioTradeABBV/USDTTrading$260.220.0% APR
0.000% every 8h		+188.4 bps$1.9K$3K$27.5KUSDT20x
BingXTradeABBV-USDTWatchlist------USDT-

Other Healthcare perps

Also listed on Gate.io

Embed this asset

ABBV perpetuals · perpequities.comABBV perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/abbv-perp"><img src="https://perpequities.com/badge/abbv-perp.svg" width="240" height="64" alt="ABBV perpetuals · perpequities.com" loading="lazy"></a>

Raw data: JSON · CSV · API

Tradability

Execution quality

No sufficient depth · 0 of 1 venues absorb $10k

No fresh book data: Gate.io

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

ABBV
Gate.io · ABBV/USDT$1.9K

Tightest spread

ABBV
Gate.io · ABBV/USDT+188.4 bps

Highest volume

ABBV
Gate.io · ABBV/USDT$3K

Funding history

Stored venue snapshots by market

Company data

Company fundamentals

Updated 4h ago
Market cap
$459.9B
Updated 4h ago
Revenue
$64.4B
Trailing 12 months
Revenue growth
+11%
Next fiscal year
Profit margin
+9.8%
P/E
73.3
Peer P/E 26.6
Free cash flow
$19.7B
Trailing 12 months
More metrics
Net income
$6.3B
Trailing 12 months
P/S
7.1
Peer P/E
26.6
Similar listed perps
Revenue estimate
$67.6B
Next fiscal year
Earnings
2026-10-30
Revenue est. $17.3B · Updated 4h ago
Dividend
$1.73
2026-07-15

Fundamental detail

Annual + quarterly
Latest revenue$61.2B
Net margin+6.9%
Free cash flow$17.8B
Net debt$63.8B
2020$45.8B
2021$56.2B
2022$58.1B
2023$54.3B
2024$56.3B
2025$61.2B
PeriodRevenueGrowthNet incomeFCF
2020$45.8B+38%$4.6B$16.8B
2021$56.2B+23%$11.5B$22B
2022$58.1B+3%$11.8B$24.2B
2023$54.3B-6%$4.9B$22.1B
2024$56.3B+4%$4.3B$17.8B
2025$61.2B+9%$4.2B$17.8B
PeriodGross marginOperating marginNet marginROEROA
2020+66.4%+24.8%+10.1%+35.3%+3.1%
2021+69.0%+31.9%+20.5%+74.9%+7.9%
2022+70.0%+31.2%+20.4%+68.6%+8.5%
2023+62.4%+23.5%+9.0%+46.9%+3.6%
2024+70.0%+16.2%+7.6%+128.7%+3.2%
2025+70.2%+32.8%+6.9%-129.2%+3.2%
PeriodCashDebtNet debtCurrent ratio
2020$8.4B$87.1B$78.6B0.84
2021$9.7B$77.6B$67.8B0.79
2022$9.2B$64.2B$55B0.96
2023$12.8B$60.1B$47.3B0.87
2024$5.5B$67.8B$62.3B0.66
2025$5.2B$69.1B$63.8B0.67
PeriodMarket capEnterprise valueP/SP/E
2020$178.6B$257.2B3.939.2
2021$239.7B$307.5B4.320.9
2022$286.2B$341.2B4.924.3
2023$274B$321.3B5.056.8
2024$314.4B$376.7B5.674.0
2025$405.3B$469.2B6.696.4
Q3 2024$14.5B
Q4 2024$15.1B
Q1 2025$13.3B
Q2 2025$15.4B
Q3 2025$15.8B
Q4 2025$16.6B
Q1 2026$15B
Q2 2026$17B
PeriodRevenueGrowthNet incomeFCF
Q3 2024$14.5B+4%$1.6B$5.2B
Q4 2024$15.1B+6%-$22M$6.8B
Q1 2025$13.3B+8%$1.3B$1.4B
Q2 2025$15.4B+7%$938M$4.9B
Q3 2025$15.8B+9%$186M$7.5B
Q4 2025$16.6B+10%$1.8B$4.9B
Q1 2026$15B+12%$699M$3.6B
Q2 2026$17B+10%$3.6B$3.7B
PeriodGross marginOperating marginNet marginROEROA
Q3 2024+70.9%+26.5%+10.8%+25.9%+1.1%
Q4 2024+70.9%-9.9%-0.1%-0.7%0.0%
Q1 2025+70.0%+28.0%+9.6%+90.6%+0.9%
Q2 2025+71.8%+31.7%+6.1%-512.6%+0.7%
Q3 2025+66.4%+12.1%+1.2%-7.0%+0.1%
Q4 2025+72.6%+35.0%+10.9%-55.5%+1.4%
Q1 2026+71.9%+31.6%+4.7%-10.5%+0.5%
Q2 2026+74.7%+37.9%+21.3%-60.9%+2.7%
PeriodCashDebtNet debtCurrent ratio
Q3 2024$7.3B$71.1B$63.8B0.65
Q4 2024$5.5B$67.8B$62.3B0.66
Q1 2025$5.2B$69.9B$64.7B0.76
Q2 2025$6.5B$70.5B$64B0.74
Q3 2025$5.6B$68.7B$63.1B0.72
Q4 2025$5.2B$68.9B$63.6B0.67
Q1 2026$9.4B$72.9B$63.5B0.80
Q2 2026$6.6B$70.8B$64.3B0.81
PeriodMarket capEnterprise valueP/SP/E
Q3 2024$349.3B$413.2B24.256.1
Q4 2024$314.4B$376.7B20.8-2,454.4
Q1 2025$370.4B$435.1B27.872.8
Q2 2025$328.9B$392.9B21.387.6
Q3 2025$410.3B$473.4B26.0581.8
Q4 2025$405.3B$469B24.456.0
Q1 2026$385.8B$449.3B25.7139.4
Q2 2026$445.7B$509.9B26.230.8
Historical value series
Revenue
Q3 2023: $13.9BQ4 2023: $14.3BQ1 2024: $12.3BQ2 2024: $14.5BQ3 2024: $14.5BQ4 2024: $15.1BQ1 2025: $13.3BQ2 2025: $15.4BQ3 2025: $15.8BQ4 2025: $16.6BQ1 2026: $15BQ2 2026: $17BQ3 2023Q2 2026
Net income
Q3 2023: $1.8BQ4 2023: $822MQ1 2024: $1.4BQ2 2024: $1.4BQ3 2024: $1.6BQ4 2024: -$22MQ1 2025: $1.3BQ2 2025: $938MQ3 2025: $186MQ4 2025: $1.8BQ1 2026: $699MQ2 2026: $3.6BQ3 2023Q2 2026
EBITDA
Q3 2023: $4.7BQ4 2023: $3.9BQ1 2024: $4.5BQ2 2024: $5BQ3 2024: $4.9BQ4 2024: $535MQ1 2025: $4.4BQ2 2025: $4.3BQ3 2025: $3.5BQ4 2025: $5.4BQ1 2026: $3.7BQ2 2026: $8.7BQ3 2023Q2 2026
Free cash flow
Q3 2023: $7.4BQ4 2023: $4.5BQ1 2024: $3.8BQ2 2024: $2BQ3 2024: $5.2BQ4 2024: $6.8BQ1 2025: $1.4BQ2 2025: $4.9BQ3 2025: $7.5BQ4 2025: $4.9BQ1 2026: $3.6BQ2 2026: $3.7BQ3 2023Q2 2026
EPS
Q3 2023: $1Q4 2023: $0.46Q1 2024: $0.77Q2 2024: $0.77Q3 2024: $0.88Q4 2024: -$0.02Q1 2025: $0.72Q2 2025: $0.53Q3 2025: $0.1Q4 2025: $1.02Q1 2026: $0.39Q2 2026: $2.04Q3 2023Q2 2026
Cash / Debt
Q3 2023 · Cash: $13.3BQ3 2023 · Debt: $60.7BQ4 2023 · Cash: $12.8BQ4 2023 · Debt: $60.1BQ1 2024 · Cash: $18.1BQ1 2024 · Debt: $74BQ2 2024 · Cash: $13.1BQ2 2024 · Debt: $70.6BQ3 2024 · Cash: $7.3BQ3 2024 · Debt: $71.1BQ4 2024 · Cash: $5.5BQ4 2024 · Debt: $67.8BQ1 2025 · Cash: $5.2BQ1 2025 · Debt: $69.9BQ2 2025 · Cash: $6.5BQ2 2025 · Debt: $70.5BQ3 2025 · Cash: $5.6BQ3 2025 · Debt: $68.7BQ4 2025 · Cash: $5.2BQ4 2025 · Debt: $68.9BQ1 2026 · Cash: $9.4BQ1 2026 · Debt: $72.9BQ2 2026 · Cash: $6.6BQ2 2026 · Debt: $70.8BQ3 2023Q2 2026
CashDebt
Profitability
Q3 2023 · Gross margin: +53.4%Q4 2023 · Gross margin: +60.1%Q1 2024 · Gross margin: +66.7%Q2 2024 · Gross margin: +70.9%Q3 2024 · Gross margin: +70.9%Q4 2024 · Gross margin: +70.9%Q1 2025 · Gross margin: +70.0%Q2 2025 · Gross margin: +71.8%Q3 2025 · Gross margin: +66.4%Q4 2025 · Gross margin: +72.6%Q1 2026 · Gross margin: +71.9%Q2 2026 · Gross margin: +74.7%Q3 2023 · Operating margin: +16.4%Q4 2023 · Operating margin: +22.3%Q1 2024 · Operating margin: +22.7%Q2 2024 · Operating margin: +27.6%Q3 2024 · Operating margin: +26.5%Q4 2024 · Operating margin: -9.9%Q1 2025 · Operating margin: +28.0%Q2 2025 · Operating margin: +31.7%Q3 2025 · Operating margin: +12.1%Q4 2025 · Operating margin: +35.0%Q1 2026 · Operating margin: +31.6%Q2 2026 · Operating margin: +37.9%Q3 2023 · Net margin: +12.8%Q4 2023 · Net margin: +5.7%Q1 2024 · Net margin: +11.1%Q2 2024 · Net margin: +9.5%Q3 2024 · Net margin: +10.8%Q4 2024 · Net margin: -0.1%Q1 2025 · Net margin: +9.6%Q2 2025 · Net margin: +6.1%Q3 2025 · Net margin: +1.2%Q4 2025 · Net margin: +10.9%Q1 2026 · Net margin: +4.7%Q2 2026 · Net margin: +21.3%Q3 2023Q2 2026
Gross marginOperating marginNet margin
Revenue growth
Q2 2024: +4.3%Q3 2024: +3.8%Q4 2024: +5.6%Q1 2025: +8.4%Q2 2025: +6.6%Q3 2025: +9.1%Q4 2025: +10.0%Q1 2026: +12.4%Q2 2026: +10.2%Q3 2023Q2 2026
Shares outstanding
Q3 2023: 1.8BQ4 2023: 1.8BQ1 2024: 1.8BQ2 2024: 1.8BQ3 2024: 1.8BQ4 2024: 1.8BQ1 2025: 1.8BQ2 2025: 1.8BQ3 2025: 1.8BQ4 2025: 1.8BQ1 2026: 1.8BQ2 2026: 1.8BQ3 2023Q2 2026
Valuation
Q3 2023 · P/E: 37.3Q4 2023 · P/E: 84.2Q1 2024 · P/E: 58.7Q2 2024 · P/E: 55.3Q3 2024 · P/E: 56.1Q4 2024 · P/E: -2,454.4Q1 2025 · P/E: 72.8Q2 2025 · P/E: 87.6Q3 2025 · P/E: 581.8Q4 2025 · P/E: 56.0Q1 2026 · P/E: 139.4Q2 2026 · P/E: 30.8Q3 2023 · P/S: 18.9Q4 2023 · P/S: 19.1Q1 2024 · P/S: 26.0Q2 2024 · P/S: 20.8Q3 2024 · P/S: 24.2Q4 2024 · P/S: 20.8Q1 2025 · P/S: 27.8Q2 2025 · P/S: 21.3Q3 2025 · P/S: 26.0Q4 2025 · P/S: 24.4Q1 2026 · P/S: 25.7Q2 2026 · P/S: 26.2Q3 2023Q2 2026
P/EP/S
Revenue
2018: $32.8B2019: $33.3B2020: $45.8B2021: $56.2B2022: $58.1B2023: $54.3B2024: $56.3B2025: $61.2B20182025
Net income
2018: $5.7B2019: $7.9B2020: $4.6B2021: $11.5B2022: $11.8B2023: $4.9B2024: $4.3B2025: $4.2B20182025
EBITDA
2018: $8.3B2019: $12.2B2020: $12.3B2021: $23.9B2022: $24.2B2023: $17.2B2024: $14.9B2025: $17.6B20182025
Free cash flow
2018: $12.8B2019: $12.8B2020: $16.8B2021: $22B2022: $24.2B2023: $22.1B2024: $17.8B2025: $17.8B20182025
EPS
2018: $3.682019: $5.282020: $2.722021: $6.452022: $6.632023: $2.722024: $2.392025: $2.3720182025
Cash / Debt
2018 · Cash: $7.3B2018 · Debt: $40.3B2019 · Cash: $39.9B2019 · Debt: $67.1B2020 · Cash: $8.4B2020 · Debt: $87.1B2021 · Cash: $9.7B2021 · Debt: $77.6B2022 · Cash: $9.2B2022 · Debt: $64.2B2023 · Cash: $12.8B2023 · Debt: $60.1B2024 · Cash: $5.5B2024 · Debt: $67.8B2025 · Cash: $5.2B2025 · Debt: $69.1B20182025
CashDebt
Profitability
2018 · Gross margin: +76.4%2019 · Gross margin: +77.6%2020 · Gross margin: +66.4%2021 · Gross margin: +69.0%2022 · Gross margin: +70.0%2023 · Gross margin: +62.4%2024 · Gross margin: +70.0%2025 · Gross margin: +70.2%2018 · Operating margin: +19.5%2019 · Operating margin: +39.0%2020 · Operating margin: +24.8%2021 · Operating margin: +31.9%2022 · Operating margin: +31.2%2023 · Operating margin: +23.5%2024 · Operating margin: +16.2%2025 · Operating margin: +32.8%2018 · Net margin: +17.4%2019 · Net margin: +23.7%2020 · Net margin: +10.1%2021 · Net margin: +20.5%2022 · Net margin: +20.4%2023 · Net margin: +9.0%2024 · Net margin: +7.6%2025 · Net margin: +6.9%20182025
Gross marginOperating marginNet margin
Revenue growth
2019: +1.6%2020: +37.7%2021: +22.7%2022: +3.3%2023: -6.4%2024: +3.7%2025: +8.6%20182025
Shares outstanding
2018: 1.5B2019: 1.5B2020: 1.7B2021: 1.8B2022: 1.8B2023: 1.8B2024: 1.8B2025: 1.8B20182025
Valuation
2018 · P/E: 25.02019 · P/E: 16.72020 · P/E: 39.22021 · P/E: 20.92022 · P/E: 24.32023 · P/E: 56.82024 · P/E: 74.02025 · P/E: 96.42018 · P/S: 4.32019 · P/S: 3.92020 · P/S: 3.92021 · P/S: 4.32022 · P/S: 4.92023 · P/S: 5.02024 · P/S: 5.62025 · P/S: 6.620182025
P/EP/S

Refreshed 4h ago

Next catalyst

Catalysts

Earnings
2026-10-30
Revenue est. $17.3B · Updated 4h ago
Dividend
$1.73
2026-07-15

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 202614.03$67.6B+11%15
FY 202716.32$73.3B+20%14
FY 202817.92$78.9B+29%8
FY 202919.80$83.5B+36%5
FY 203020.98$85.2B+39%5
Q1 20273.32$16.2B+8%4

Company events

6
2026-10-30EarningsActual - / Estimate 3.86-
2026-07-31EarningsActual 3.65 / Estimate 3.61Beat
2026-07-15Dividend$1.73-
2026-04-29EarningsActual 2.65 / Estimate 2.59Beat
2026-04-15Dividend$1.73-
2026-02-04EarningsActual 2.71 / Estimate 2.65Beat

Peer comparison

Similar listed perps
NameMarket capP/SP/EProfit marginVenues
MRK$376.3B5.7120.9+4.8%13UNH$364.1B0.825.8+3.1%8NVS$310B5.624.7+23.1%2JNJ$671B6.932.2+21.5%6AMGN$239.7B6.327.4+22.9%6NVO$211B4.111.5+35.3%13GILD$187.8B6.2-58.2-10.6%7PFE$164.2B2.638.1+6.8%3

FMP company data

Company intelligence

Updated: Sep 4, 2026, 07:01 AM UTC

Company profile

Sector
Healthcare
Industry
Drug Manufacturers - General
Chief executive
Robert A. Michael
Employees
57,000
IPO date
Jan 2, 2013
Country
US
Exchange
New York Stock Exchange
Website
Altman Z-scorei2.5
Piotroski scorei9/9
FMP ratingiC+
Owner earningsi$3.85B$2.17 per share
ESG risk ratingiBIndustry rank: 16 out of 27

Rating factors

Return on equityi
1
Return on assetsi
4
Debt to equityi
1
Price to earningsi
1
Price to booki
1

Company press releases

AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple MyelomaPRNewsWireAbbVie Completes Acquisition of Apogee TherapeuticsPRNewsWireAbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare ConferencePRNewsWireSkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare OfferingsPRNewsWireAbbVie to Present at the Wells Fargo 21st Annual Healthcare ConferencePRNewsWireAbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's DiseasePRNewsWire

Congressional disclosures

Senate

House

Market cap history
2026-06-03 – 2026-09-03Latest: $461.75BHigh: $461.75BLow: $385.16B
Largest fund holders
FundWeightShares held
VTI0.61%56.3M
VOO0.69%46.4M
VCPA.S0.66%30.8M
IVV0.68%23.6M
1657.T0.52%23.6M
XAW.TO0.4%23.6M
XUU.TO0.6%23.6M
FXAIX0.69%22M
SPY0.68%21.7M
VTV1.64%16.8M
VSCA.S0.45%13.6M
XLV7.31%12.6M

Frequently asked questions

Where can I trade ABBV perpetual futures?

AbbVie Inc. (ABBV) perpetual futures trade on 1 crypto venues, including Gate.io. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade ABBV around the clock?

Yes. Unlike the underlying stock, ABBV perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on ABBV perpetuals?

Each venue sets its own ABBV funding rate and it changes continuously. PerpEquities shows the live rate, annualized rate and history for every venue side by side.

What is a ABBV perpetual future?

A ABBV perpetual is a derivative that tracks the price of AbbVie Inc. with no expiry date. It lets you take long or short exposure to AbbVie Inc. on crypto venues, around the clock.